Sutro Biopharma Statistics
Total Valuation
Sutro Biopharma has a market cap or net worth of $476.81 million. The enterprise value is $302.01 million.
Important Dates
The next estimated earnings date is Thursday, May 7, 2026, after market close.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Sutro Biopharma has 16.57 million shares outstanding. The number of shares has increased by 9.84% in one year.
| Current Share Class | 16.57M |
| Shares Outstanding | 16.57M |
| Shares Change (YoY) | +9.84% |
| Shares Change (QoQ) | +2.91% |
| Owned by Insiders (%) | 0.94% |
| Owned by Institutions (%) | 33.13% |
| Float | 15.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.17 |
| Forward PS | 12.19 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.95 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.01
| Current Ratio | 2.01 |
| Quick Ratio | 1.94 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.50 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -23.38% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -106.34% |
| Weighted Average Cost of Capital (WACC) | 18.56% |
| Revenue Per Employee | $748,058 |
| Profits Per Employee | -$1.39M |
| Employee Count | 137 |
| Asset Turnover | 0.37 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -93,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +377.76% in the last 52 weeks. The beta is 1.31, so Sutro Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.31 |
| 52-Week Price Change | +377.76% |
| 50-Day Moving Average | 21.30 |
| 200-Day Moving Average | 12.51 |
| Relative Strength Index (RSI) | 70.42 |
| Average Volume (20 Days) | 245,801 |
Short Selling Information
The latest short interest is 639,714, so 3.86% of the outstanding shares have been sold short.
| Short Interest | 639,714 |
| Short Previous Month | 532,614 |
| Short % of Shares Out | 3.86% |
| Short % of Float | 4.22% |
| Short Ratio (days to cover) | 3.73 |
Income Statement
In the last 12 months, Sutro Biopharma had revenue of $102.48 million and -$191.09 million in losses. Loss per share was -$22.49.
| Revenue | 102.48M |
| Gross Profit | -63.93M |
| Operating Income | -104.95M |
| Pretax Income | -191.18M |
| Net Income | -191.09M |
| EBITDA | -97.63M |
| EBIT | -104.95M |
| Loss Per Share | -$22.49 |
Full Income StatementBalance Sheet
The company has $141.43 million in cash and $15.67 million in debt, with a net cash position of $125.75 million or $7.59 per share.
| Cash & Cash Equivalents | 141.43M |
| Total Debt | 15.67M |
| Net Cash | 125.75M |
| Net Cash Per Share | $7.59 |
| Equity (Book Value) | -132.45M |
| Book Value Per Share | -15.43 |
| Working Capital | 75.79M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$177.23 million and capital expenditures -$1.70 million, giving a free cash flow of -$178.93 million.
| Operating Cash Flow | -177.23M |
| Capital Expenditures | -1.70M |
| Depreciation & Amortization | 7.32M |
| Net Borrowing | n/a |
| Free Cash Flow | -178.93M |
| FCF Per Share | -$10.80 |
Full Cash Flow StatementMargins
Gross margin is -62.38%, with operating and profit margins of -102.41% and -186.45%.
| Gross Margin | -62.38% |
| Operating Margin | -102.41% |
| Pretax Margin | -186.55% |
| Profit Margin | -186.45% |
| EBITDA Margin | -95.26% |
| EBIT Margin | -102.41% |
| FCF Margin | n/a |
Dividends & Yields
Sutro Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.84% |
| Shareholder Yield | -9.84% |
| Earnings Yield | -44.67% |
| FCF Yield | -41.83% |
Analyst Forecast
The average price target for Sutro Biopharma is $26.38, which is -8.34% lower than the current price. The consensus rating is "Buy".
| Price Target | $26.38 |
| Price Target Difference | -8.34% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | -14.53% |
| EPS Growth Forecast (5Y) | -40.10% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 3, 2025. It was a reverse split with a ratio of 1:10.
| Last Split Date | Dec 3, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
Sutro Biopharma has an Altman Z-Score of -8.58 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -8.58 |
| Piotroski F-Score | 3 |
